Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, a subsidiary of AstraZeneca, to develop cholesterol medications to treat dyslipidemia, including hypertriglyceridemia. The research will target the development of novel products using Ligand’s LTP Technology to improve lipid-lowering activity of certain omega-3 fatty acids.   Ligand will be eligible to receive payments of as much as $44.5 million for the achievement of certain m...